Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across non–small cell lung cancer (NSCLC) histologies and is Food and Drug Administration approved for treatment of metastatic squamous NSCLC with progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Therese, Simmons, Pauline, Inzunza, Hector D., Cogswell, John, Novotny, James, Taylor, Clive, Zhang, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561627/
https://www.ncbi.nlm.nih.gov/pubmed/26317305
http://dx.doi.org/10.1097/PAI.0000000000000256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561627/
https://www.ncbi.nlm.nih.gov/pubmed/26317305
http://dx.doi.org/10.1097/PAI.0000000000000256

Ejemplares similares